3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow LPM3770164 sustained release tablet: new trials by email Literature Review of LPM3770164 sustained release tablet trials Research Report on LPM3770164 sustained release tablet
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets LPM3770164 sustained release tablet - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 16 | 2024-07-31 | 2024-12-12 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Tardive Dyskinesia, Huntington Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 40 | 2023-12-19 | 2024-12-12 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 104 | 2022-02-25 | 2024-01-29 |
Huntington Disease (3) · Tardive Dyskinesia (3)
China (3)
Huafang Li, Doctor (1) · Hufang Li, Doctor (1)